Status:
COMPLETED
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
Lead Sponsor:
Pfizer
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Statin eligible per NCEP ATP-III guidelines
- At least 18 years of age
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant
- Intolerance to statin therapy
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT00137462
Start Date
November 1 2004
End Date
September 1 2006
Last Update
November 16 2007
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35802
2
Pfizer Investigational Site
Union Grove, Alabama, United States, 35175
3
Pfizer Investigational Site
Fresno, California, United States, 93720
4
Pfizer Investigational Site
Los Angeles, California, United States, 90057